Mycosis fungoides (MF) may involve more than just the skin1
As the most common cutaneous T-cell lymphoma (CTCL) subtype, MF may be indolent with skin-only symptoms, but may progress to the blood, lymph nodes, and viscera
1 in 3 patients with MF
experience progression within skin or to other compartments, including blood2,3
in mycosis fungoides (MF):
May be more common than you think4
May impact outcomes2
CTCL Expert Perspectives: Patient Identification
Andrei Shustov, MD discusses identifying therapy-refractive patients, how blood involvement can impact treatment selection, how clinical practice guidelines help shape decisions, and appropriate patient types for treatment with POTELIGEO based on data from the phase 3 MAVORIC trial.
Blood testing for suspected mycosis fungoides (MF) is important at diagnosis and throughout treatment to monitor disease burden and response to treatment5See how POTELIGEO responds in skin
- Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.
- Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730-4739.
- Amorim GM, Niemeyer-Corbellini JP, Quintella DC, Cuzzi T, Ramos-E-Silva M. Clinical and epidemiological profile of patients with early stage mycosis fungoides. An Bras Dermatol. 2018;93(4):546-552.
- Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-1722.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Primary Cutaneous Lymphomas V.1.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed 05-18-2021. To view the most recent and complete version of the guideline, go online to NCCN.org.